The effect of mefenamic acid, naproxen and placebo on periodic bleeding in women

The effect of mefenamic acid and naproxen on the amount of heavy menstrual bleeding in women of reprodcutive age: a placebo-?controlled study.?

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201204241548N14

Enrollment

120

Registered

2012-05-05

Start date

2012-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heavy menstrual bleeding. Excessive and frequent menstruation with irregular cycle

Interventions

Intervention 1: Participants in the first group will receive tablets containing 250 mg of mefenamic acid four times ?daily (1000 mg total daily intake)from day 1 to day 7 of ?each menstrual cycle. Int

Treatment - Drugs

Placebo

Participants in the first group will receive tablets containing 250 mg of mefenamic acid four times ?daily (1000 mg total daily intake)from day 1 to day 7 of ?each menstrual cycle.

Participants in the second group will receive tablets containing 250 mg of naproxen four times ?daily (1000 mg total daily intake) from day 1 to day 7 of each menstrual cycle.?

Participants in the third group will receive placebo tablets four times daily from day 1 to day ??7 of each menstrual cycle.?

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were the followings: a) being between 20 and 45 years old of age; b) normal ?results for cervical smear test; c) negative history of renal or hepatic impairment, ?thromboembolic disease, inflammatory bowel disease, peptic or intestinal ulceration, ?coagulation or fibrinolytic disorders; d) normal results for blood tests (including PT, PTT, BT, ?TSH); e) not taking any hormones and NSAIDS.? Exclusion criteria included: a) infertility; b) overweight/obesity (BMI>25) or underweight ??(BMI<18.5); c) polycystic ovaries; d) vaginitis and/or pelvic inflammatory disease (PID); e) ?uterine polyps and/or fibroids; f) carrying IUD; g) being perimenopausal (increased serum ?FSH showed being premenopausal). ?

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Amount of menstrual bleeding. Timepoint: One month. Method of measurement: Pictorial Blood Assessment Chart ?.	—

Secondary

Measure	Time frame
Decrease in the amount of menstrual bleeding. Timepoint: one month. Method of measurement: Pictorial Blood Assessment Chart ?.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhadijeh Abdali

Fatemeh College of Nursing and Midwifery, Shiraz University of Medical Sciences

abdalikh@sums.ac.ir+98 71164742528

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026